These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 35433771)

  • 1. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.
    Chung T; Park YN
    Front Med (Lausanne); 2022; 9():857140. PubMed ID: 35433771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
    Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
    Choi JH; Thung SN
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
    Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
    Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
    Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
    Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.
    Akita M; Sofue K; Fujikura K; Otani K; Itoh T; Ajiki T; Fukumoto T; Zen Y
    HPB (Oxford); 2019 Feb; 21(2):226-234. PubMed ID: 30170977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.
    Akita M; Yanagimoto H; Tsugawa D; Zen Y; Fukumoto T
    Surg Today; 2024 Apr; ():. PubMed ID: 38563999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
    Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
    J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
    J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.